Ireland· IE-PA-EU/1/05/315/002
Aptivus
A protease inhibitors product containing tipranavir, registered in Ireland by Boehringer Ingelheim International GmbH. The same ATC class is registered in 2 of our 19 countries.
Checked against HPRA (Ireland) on
Informational only — not a medical device.
Where it is registered
Tipranavir is registered in 2 of 19 countries.
Countries holding a registration under ATC J05AE (protease inhibitors), each read from that country’s own register.
- This record: Ireland, from HPRA (Ireland)
- 1 of them publish a price we can compare per daily dose
Tipranavir · ATC J05AE
2 / 19 countries
- Belgiumprice
- Ireland
The record
At a glance
HPRA (Ireland)- Active substance
- Tipranavir
- Manufacturer
- Boehringer Ingelheim International GmbH
- Country
- Ireland (IE)
- ATC code
- J05AE
- ATC class
- Protease inhibitors
- Reimbursed
- Not published by this register
- Source register
- HPRA (Ireland)
- Last checked
- September 28, 2026
Packs & prices · 1
- ie_pa_numberEU/1/05/315/002
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Tipranavir in 12 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumAptivus 100 mg/mlBoehringer Ingelheim International
- SpainAPTIVUS 100 MG/ML SOLUCION ORALBoehringer Ingelheim International Gmbh
- FinlandAptivusBoehringer Ingelheim International GmbH
- United KingdomAptivus 100mg/ml oral solutionBoehringer Ingelheim Ltd
- IcelandAptivusBoehringer Ingelheim International GmbH*
- NetherlandsAptivus 100 mg/ml, drankBoehringer Ingelheim International GmbH
- SwedenAptivus 100 mg/ml Oral lösningBoehringer Ingelheim International GmbH
- CanadaAPTIVUSBOEHRINGER INGELHEIM (CANADA) LTD LTEE
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Aptivus
- Liechtenstein · Aptivus
- Norway · Aptivus
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/6092de3b-f532-435d-b6eb-dcfea4c0518c GET /v1/drugs/6092de3b-f532-435d-b6eb-dcfea4c0518c?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Oral solution",
"routes": [
"Oral use"
],
"source": "hpra",
"atc_all": [
"J05AE"
],
"strength": null,
"pa_number": "EU/1/05/315/002",
"substances": [
"Tipranavir"
],
"legal_basis": "Full application (Article 8(3) of Directive No 2001/83/EC)",
"market_info": "Unknown",
"authorised_at": "23/06/2009",
"dispensing_status": "Product subject to Restricted Prescription (C)",
"registration_status": "AU",
"supply_legal_status": "Supply through pharmacies only",
"interchangeable_code": null
}See everything about tipranavir.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.